Hernán MA, Robins JM. Using big data to emulate a target trial when a randomized trial is not available. Am J Epidemiol. 2016;183:758–64.

Article  PubMed  PubMed Central  Google Scholar 

Hernán MA, Alonso A, Logan R, et al. Observational studies analyzed like randomized experiments: an application to postmenopausal hormone therapy and coronary heart disease. Epidemiology. 2008;19:766–79.

Article  PubMed  PubMed Central  Google Scholar 

Tannen RL, Weiner MG, Xie D. Use of primary care electronic medical record database in drug efficacy research on cardiovascular outcomes: comparison of database and randomised controlled trial findings. BMJ (Online). 2009;338:395–9.

Google Scholar 

Danaei G, Tavakkoli M, Hernán MA. Bias in observational studies of prevalent users: lessons for comparative effectiveness research from a meta-analysis of statins. Am J Epidemiol. 2012;175:250–62.

Article  PubMed  PubMed Central  Google Scholar 

Petito LC, García-Albéniz X, Logan RW, et al. Estimates of overall survival in patients with cancer receiving different treatment regimens. JAMA Netw Open. 2020;3:1–13.

Article  Google Scholar 

Lodi S, Phillips A, Lundgren J, et al. Effect estimates in randomized trials and observational studies: comparing apples with apples. Am J Epidemiol. 2019;188:1569–77.

Article  PubMed  PubMed Central  Google Scholar 

Artibani W, Porcaro AB, De Marco V, et al. Management of biochemical recurrence after primary curative treatment for prostate cancer: a review. Urol Int. 2018;100:251–62.

Article  CAS  PubMed  Google Scholar 

Higano CS. Intermittent versus continuous androgen deprivation therapy. J Natl Compr Canc Netw. 2014;12:727–33.

Article  PubMed  Google Scholar 

Nguyen PL, Alibhai SMH, Basaria S, et al. Adverse effects of androgen deprivation therapy and strategies to mitigate them. Eur Urol. 2015;67:825–36.

Article  CAS  PubMed  Google Scholar 

Orellana L, Rotnitzky A, Robins JM. Dynamic regime marginal structural mean models for estimation of optimal dynamic treatment regimes, Part I: main content. Int J Biostat. 2010;6:44398–9.

Google Scholar 

Cain LE, Robins JM, Lanoy E, et al. When to start treatment? A systematic approach to the comparison of dynamic regimes using observational data. Int J Biostat. 2010;6:1–42.

Article  Google Scholar 

Robins J. A graphical approach to the identification and estimation of causal parameters in mortality studies with sustained exposure periods. J Chronic Dis. 1987;40(Suppl 2):139S-161S.

Article  PubMed  Google Scholar 

Young JG, Cain LE, Robins JM, et al. Comparative effectiveness of dynamic treatment regimes: an application of the parametric g-formula. Stat Biosci. 2011;3:119–43.

Article  PubMed  PubMed Central  Google Scholar 

Garcia-Albeniz X, Chan JM, Paciorek A, et al. Immediate versus deferred initiation of androgen deprivation therapy in prostate cancer patients with PSA-only relapse. An observational follow-up study. Eur J Cancer. 2015;51:817–24.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Duchesne GM, Woo HH, Bassett JK, et al. Timing of androgen-deprivation therapy in patients with prostate cancer with a rising PSA (TROG 03.06 and VCOG PR 01–03 [TOAD]): A randomised, multicentre, non-blinded, phase 3 trial. Lancet Oncol. 2016;17:727–37.

Article  CAS  PubMed  Google Scholar 

Loblaw A, Bassett J, D’Este C, et al. Timing of androgen deprivation therapy for prostate cancer patients after radiation: Planned combined analysis of two randomized phase 3 trials. J Clin Oncol. 2018;36:5018–5018.

Article  Google Scholar 

Klayton TL, Ruth K, Buyyounouski MK, et al. Prostate-specific antigen doubling time predicts the development of distant metastases for patients who fail 3-dimensional conformal radiotherapy or intensity modulated radiation therapy using the Phoenix definition. Pract Radiat Oncol. 2011;1:235–42.

Article  PubMed  PubMed Central  Google Scholar 

Hernán MA, Robins JM. Per-protocol analyses of pragmatic trials. N Engl J Med. 2017;377:1391–8.

Article  PubMed  Google Scholar 

Pound CR, Partin AW, Eisenberger MA, et al. Natural history of progression after PSA. J Am Med Assoc. 1999;281:1591–7.

Article  CAS  Google Scholar 

Robins JM, Finkelstein DM. Correcting for noncompliance and dependent censoring in an AIDS clinical trial with inverse probability of censoring weighted (IPCW) log-rank tests. Biometrics. 2000;56:779–88.

Article  CAS  PubMed  Google Scholar 

Lubeck DP, Litwin MS, Henning JM, et al. The CaPSURE database: a methodology for clinical practice and research in prostate cancer. Urology. 1996;48:773–7.

Article  CAS  PubMed  Google Scholar 

Cooperberg MR, Broering JM, Litwin MS, et al. The contemporary management of prostate cancer in the United States: lessons from the cancer of the prostate strategic urologic research Endeavor (CaPSURE), a national disease registry. J Urol. 2004;171:1393–401.

Article  PubMed  Google Scholar 

Studer UE, Collette L, Whelan P, et al. Using PSA to guide timing of androgen deprivation in patients with T0–4 N0–2 M0 prostate cancer not suitable for local curative treatment (EORTC 30891). Eur Urol. 2008;53:941–9.

Article  PubMed  Google Scholar 

R Core Team. R 3.4.3. 2017.

McGrath S, Lin V, Zhang Z, et al. gfoRmula: An R package for estimating the effects of sustained treatment strategies via the parametric g-formula. Patterns. 2020;1: 100008.

Article  CAS  PubMed  PubMed Central  Google Scholar 

NCCN Clinical Practice Guidelines in Oncology. Prostate Cancer. National Comprehensive Cancer Network; 2018.

Lonergan PE, Washington SL, Cowan, JE, et al. Androgen deprivation therapy and the risk of dementia after treatment for prostate cancer. J Urol. 2021; epub ahead of print.

Botrel TEA, Clark O, dos Reis RB, et al. Intermittent versus continuous androgen deprivation for locally advanced, recurrent or metastatic prostate cancer: a systematic review and meta-analysis. BMC Urol. 2014;14:9.

Article  PubMed  PubMed Central  Google Scholar